Piramal Life Sciences Ltd, part of the Piramal Group of companies, has commenced a phase I study of a new, orally active glucose-lowering compound, P1736, in The Netherlands.
P1736 is a non-PPAR compound and is being developed for the treatment of type II diabetes. The compound is significantly different from the currently marketed drugs, as it does not have any adverse side effects on liver function, blood plasma volume expansion or those related to weight gain.
The details can be read here.
No comments:
Post a Comment